相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Characterization of Driver Mutations in Anaplastic Thyroid Carcinoma IdentifiesRASandPIK3CAMutations as Negative Survival Predictors
Wei-An Lai et al.
CANCERS (2020)
Effect of Sepatronium Bromide (YM-155) on DNA Double-Strand Breaks Repair in Cancer Cells
Dusana Majera et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Sodium sulfide selectively induces oxidative stress, DNA damage, and mitochondrial dysfunction and radiosensitizes glioblastoma (GBM) cells
Adam Y. Xiao et al.
REDOX BIOLOGY (2019)
Early Cellular Responses of Prostate Carcinoma Cells to Sepantronium Bromide (YM155) Involve Suppression of mTORC1 by AMPK
David Danielpour et al.
SCIENTIFIC REPORTS (2019)
Quinone-Based Antitumor Agent Sepantronium Bromide (YM155) Causes Oxygen-Independent Redox-Activated Oxidative DNA Damage
Tasaduq H. Wani et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2018)
ATR/CHK1 inhibitors and cancer therapy
Zhaojun Qiu et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Adaptation to chronic exposure to sepantronium bromide (YM155), a prototypical survivin suppressant is due to persistent DNA damage-response in breast cancer cells
Tasaduq H. Wani et al.
Oncotarget (2018)
Therapeutic advances in anaplastic thyroid cancer: a current perspective
Shikha Saini et al.
MOLECULAR CANCER (2018)
Differentiated and Anaplastic Thyroid Carcinoma: Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual
Nancy D. Perrier et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Survivin Inhibitor YM155 Induces Mitochondrial Dysfunction, Autophagy, DNA Damage, and Apoptosis in Bcl-xL Silenced Glioma Cell Lines
Esther P. Jane et al.
MOLECULAR CARCINOGENESIS (2017)
Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study
Ashish V. Chintakuntlawar et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Validation of JCountPro software for efficient assessment of ionizing radiation-induced foci in human lymphocytes
Lukas Jakl et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2016)
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Inigo Lancia et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Primary Cell Culture Systems for Human Thyroid Studies
Yanqiang Wang et al.
THYROID (2016)
The Mechanism of Radiosensitization by YM155, a Novel Small Molecule Inhibitor of Survivin Expression, is Associated with DNA Damage Repair
Songliu Hu et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2015)
Cell cycle regulation of human DNA repair and chromatin remodeling genes
Robin Mjelle et al.
DNA REPAIR (2015)
YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway
Bill H. Chang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer
Michael R. Clemens et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells
S. M. Cheng et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Roles of Chk1 in cell biology and cancer therapy
Youwei Zhang et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer
R. J. Kelly et al.
ANNALS OF ONCOLOGY (2013)
YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells
Weiying Feng et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
The survivin suppressants NSC 80467 and YM155 induce a DNA damage response
Trevor G. Glaros et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin
Naoto Nakamura et al.
MOLECULAR & CELLULAR PROTEOMICS (2012)
Factors determining DNA double-strand break repair pathway choice in G2 phase
Atsushi Shibata et al.
EMBO JOURNAL (2011)
γH2AX foci as a measure of DNA damage: A computational approach to automatic analysis
Alesia N. Ivashkevich et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2011)
Detailed Molecular Fingerprinting of Four New Anaplastic Thyroid Carcinoma Cell Lines and Their Use for Verification of RhoB as a Molecular Therapeutic Target
Laura A. Marlow et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non-Small-Cell Lung Cancer
Giuseppe Giaccone et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Investigating Oxidative DNA damage and its repair using the comet assay
Andrew R. Collins
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2009)
Anaplastic thyroid cancer
Ryan L. Neff et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2008)
Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells
SH Chung et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2002)
Oxidation of biological systems: Oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification
A Nyska et al.
TOXICOLOGIC PATHOLOGY (2002)
分享论文
